Astrazeneca (AZN) Cash from Restructuring (2009 - 2014)

Astrazeneca (AZN) has reported Cash from Restructuring for 6 consecutive years, with $84.3 million the latest figure, recorded in Q2 2014.

• In Q2 2014, Cash from Restructuring rose 1304.6% year-over-year to $84.3 million; the TTM figure through Dec 2016 stood at $84.3 million (changed N/A YoY), while the FY2016 annual figure was -$9.7 million, changed N/A from the prior year.
• Cash from Restructuring came in at $84.3 million for Q2 2014 at Astrazeneca, up from -$102.0 million in the prior quarter.
• The five-year high for Cash from Restructuring was $84.3 million in Q2 2014, with the low at -$102.0 million in Q1 2014.
• Average Cash from Restructuring over 5 years is -$7.4 million, with a median of -$5.0 million recorded in 2013.
• The largest YoY upside for Cash from Restructuring was 1304.6% in 2014 against a maximum downside of 3300.0% in 2014.
• Year by year, Cash from Restructuring stood at -$10.0 million in 2010, then surged by 90.0% to -$1.0 million in 2011, then soared by 200.0% to $1.0 million in 2012, then tumbled by 800.0% to -$7.0 million in 2013, then soared by 1304.6% to $84.3 million in 2014.
• According to Business Quant data, Cash from Restructuring over the past three periods registered $84.3 million, -$102.0 million, and -$7.0 million for Q2 2014, Q1 2014, and Q2 2013 respectively.